RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
|
Goldman Sachs 47th Annual Global Healthcare Conference |
|
|
Date: |
Tuesday, June 9, 2026 |
|
Time: |
2:40pm ET |
|
Format: |
Fireside Chat |
|
|
|
|
|
|
|
|
|
Goldman Sachs 47th Annual Global Healthcare Conference
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Investor [email protected]
Media RelationsMelyssa WeibleElixir Health Public RelationsEmail: [email protected]